IBA and SK Capital Finalize Agreement for IBA Molecular

IBA and SK Capital Finalize Agreement for IBA Molecular
New Company Poised for Future Growth and Continued Industry Leadership

Louvain-La-Neuve, Belgium, April 2, 2012 - IBA (Ion Beam Applications S.A.) and SK Capital Partners, a U.S. based private investment firm, announced that they have finalized their agreement to create IBA Molecular, a jointly owned company derived from IBA's worldwide radiopharmaceutical division. IBA
Molecular is a world-wide leader in the manufacturing and distribution of radioactive isotopes used for medical imaging and therapy, with over 50 locations in the U.S., Europe and Asia and employs over 1,000 people.

As an independent, focused radiopharmaceutical company, IBA Molecular will be better able to take advantage of its recently upgraded manufacturing and distribution platform and will seek to expand its research, manufacturing and product partnerships. The company will continue its commitment to deliver
value to its customers with innovative marketing programs for molecular imaging and therapy. Its initiatives in education and support are resulting in improved quality, better service, and more appropriate utilization of PET imaging in the U.S., and both PET and SPECT imaging in Europe and Asia.

As IBA's new partner, SK Capital brings significant investment and operating experience in diagnostic imaging, as well as pharmaceutical manufacturing, development and distribution, all of which will benefit IBA Molecular. SK Capital's investment goal is to strengthen the company's radiopharmaceutical capabilities by streamlining its manufacturing operations, enhancing the quality and reliability of its products and services, and expanding its geographic presence. This agreement also provides for continued investment in the ongoing development of IBA Molecular's pipeline of innovative PET and SPECT products.

Jamshid Keynejad, a Managing Director of SK Capital and new Chairman of the Board for IBA Molecular, noted "We are pleased to be involved in this new endeavor and in further developing a company with a solid foundation and significant potential for future growth. The vibrancy and dedication
of the people at every level in IBA Molecular is quite distinct. They are clearly on a mission to positively impact healthcare, and we are pleased to join them in that effort."

Renaud Dehareng, formerly President of the IBA Group radiopharmaceutical division, and now Chief Executive Officer of IBA Molecular, said "The creation of this new company with SK Capital really solidifies our commitment and leadership in the molecular imaging marketplace. SK Capital brings expertise and access to capital, which will positively affect our manufacturing, distribution, product pipeline, and customer support."


About IBA Molecular

IBA Molecular is a global developer, manufacturer and distributor of radiopharmaceutical products and supporting services used in molecular imaging. IBA Molecular has engineered a strong and unique product portfolio and pipeline of diagnostic and therapeutic tracers aimed at advancing the
development of the global movement towards personalized medicine and making molecular imaging/therapy a major discipline in healthcare. The company also provides educational, technical and marketing support to medical specialists worldwide to help better respond to patient needs.

Please visit http://www.iba-molecular.com for more information about IBA Molecular.

About SK Capital

SK Capital is a private investment firm with a disciplined focus on the specialty materials, chemicals and healthcare sectors. Our integrated, multi-disciplinary team utilizes its industry, operating and investment experience to help transform businesses into higher performing organizations. Located in
New York, NY and Boca Raton, FL, we are currently investing from SK Capital Partners III, L.P., a $500 million fund of committed capital. Our portfolio companies generate revenues of over $3.0 billion annually and employ more than 3,400 people.

Please visit http://www.skcapitalpartners.com for more information about SK Capital.

Contact:
IBA Molecular
Randall Mastrangelo
Vice President, Marketing
E-mail: [email protected]

SK Capital Partners
Jamshid Keynejad
Managing Director
E-mail: [email protected]

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.